IMR Press / EJGO / Volume 41 / Issue 1 / DOI: 10.31083/j.ejgo.2020.01.4886
Open Access Original Research
Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer
Show Less
1 Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
2 Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan
Eur. J. Gynaecol. Oncol. 2020, 41(1), 93–97;
Published: 15 February 2020

Purpose of Investigation: The aim of this study was to evaluate whether leukocytosis and thrombocytosis prior to treatment was associated with the prognosis of women with uterine cervical cancer. Materials and Methods: The authors assessed 2,267 women who were diagnosed as having FIGO Stages I-IV uterine cervical cancer and were followed up for at least five years. The age, clinical stage, histology, leukocytosis, and thrombocytosis at the initial diagnosis were evaluated for overall survival (OS). Results: Leukocytosis and thrombocytosis were identified in 315 and in 134 women, respectively. Fifty-eight had both conditions. Multivariable analysis revealed that age [hazard ratio (HR) 1.7, p < 0.001], advanced FIGO Stage (4.8, p < 0.001), histology (2.0, p < 0.001), leukocytosis (1.5, p < 0.01), and thrombocytosis (2.0, p < 0.01) were independent factors for decreased OS. OS of women with both thrombocytosis and leukocytosis was the worst (p < 0.01). Conclusion: Leukocytosis and thrombocytosis were independently associated with decreased OS in women with uterine cervical cancer.

Cervical cancer
Figure 1.
Back to top